n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime has been researched along with Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fardini, Y; Hampe, C; Issad, T; Kanwal, S; Masson, E; N'tumba-Byn, T; Pagesy, P; Pierre-Eugène, C | 1 |
1 other study(ies) available for n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime and Breast Cancer
| Article | Year |
|---|---|
O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
Topics: Acetylglucosamine; Antineoplastic Agents, Hormonal; Biosynthetic Pathways; Breast Neoplasms; Cell Death; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Hexosamines; Humans; Insulin-Like Growth Factor I; MCF-7 Cells; Oximes; Phenylcarbamates; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen | 2013 |